Ulrik Nielsen - Merrimack Pharmaceuticals Insider

Merrimack Pharmaceuticals Inc -- USA Stock  

USD 9.67  0.04  0.41%

Chief Scientific Officer and Sr. VP of Research

Dr. Ulrik B. Nielsen, Ph.D., is Director of Company. He has served as a member of our board of directors since January 2015 and is one of our cofounders. Dr. Nielsen led our research and drug discovery from when he joined us in 2002 to January 2015, including as our Senior Vice President and Chief Scientific Officer from March 2009 until January 2015. Dr. Nielsen has served as President and Chief Executive Officer of Torque Inc., a biotechnology company, since January 2015. Dr. Nielsen also served as Chief Executive Officer of Silver Creek Pharmaceuticals, Inc., a majority owned subsidiary of ours, from July 2010 to March 2014
Age: 43  SVP Since 2015      
617-441-1000  http://www.merrimack.com
Nielsen holds a Ph.D. in molecular biology and an M.S. in biochemistry from the University of Copenhagen.

Management Efficiency

The company has return on total asset (ROA) of (60.21) % which means that it has lost $60.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (19.0) % meaning that it created substantial loss on money invested by shareholders.

Similar Executives

Found 1 records

SVP Since

Reed ClarkDimension Therapeutics Inc

Entity Summary

Merrimack Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on biomarker-defined cancers in the United States. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts. Merrimack Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 72 people.Merrimack Pharmaceuticals Inc (MACK) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 72 people. Merrimack Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.

Did you try this?

Run Alpha Finder Now

Alpha Finder

Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Hide  View All  NextLaunch Alpha Finder

Fix Portfolio

Optimize Your Risk-Return Tradeoff
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Merrimack Pharmaceuticals Inc to your portfolio

Top Management

Merrimack Pharmaceuticals Leadership Team
Robert Mulroy, CEO
George Demetri, Director
Gary Crocker, Chairman, MBA
Vivian Lee, Director, MBA
James Quigley, Director, Ph.D
Birgit Schoeberl, Executive
Richard Peters, CEO, Ph.D
Ulrik Nielsen, SVP
John Mendelsohn, Director
John Green, Executive
Ellen Forest, Executive
Yasir AlWakeel, CFO, Ph.D
Edward Stewart, President, MBA
Jean Franchi, CFO, CPA
William Sullivan, Executive, MBA
William Mcclements, Executive, MBA
John Dineen, Director
Russell Ray, Director, MBA
Peter Laivins, Executive, MBA
Michael Porter, Director, MBA
Geoffrey Grande, Executive
Sergio Santillana, Executive

Stock Performance

Merrimack Pharmaceuticals Performance Indicators